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Abstract
Background: Coeliac disease is characterised by villous atrophy, which usually normalises after gluten withdrawal.
Sometimes the revaluation of duodenal histology is required during follow-up, even if the methodology for comparing
duodenal histology before and after introducing a gluten-free diet is not yet established. Our aim was to evaluate a
novel criterion to compare duodenal histology in coeliac disease before and after gluten withdrawal.
Methods: Duodenal biopsies from coeliac patients were retrospectively reviewed to compare duodenal histology at
diagnosis and after at least one year on a gluten-free diet. Two different methods were used: the first was represented
by the classical Marsh-Oberhuber score, the second compared the areas covered by each Marsh-Oberhuber grade and
expressed as percentages, the final grade being calculated from the analysis of ten power fields per duodenal biopsy.
Results: Sixty-nine patients (17 males 52 females, age at diagnosis 36 ± 15 years) who underwent duodenal biopsies,
were considered. According to the classical Marsh-Oberhuber scale, 32 patients did not present atrophy during
follow-up while 37 showed duodenal atrophy, among whom 26 improved the grade of severity and 11 retained the
same one. Of these latter, according to the second method, eight patients were considered improved, two showed a
worsened duodenal damage and only one remained unchanged; the evaluation changed in 91 % of cases.
Conclusions: The proposed semi-quantitative approach (i.e. the second method) for the evaluation of histology at
follow-up provides additional information about the progression/regression of the mucosal damage.
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Background
Coeliac disease (CD) is a common (1:100) autoimmune
disorder of the small bowel: CD is triggered by the inges-
tion of gluten in genetically susceptible subjects carrying
the HLA type II DQ2 and/or DQ8 haplotypes [1–3]. CD is
characterised by a wide variability of symptoms, ranging
from severe malabsorption to subclinical or silent pictures
as observed during screening programmes [4]. CD diagno-
sis is based on: the detection of specific auto-antibodies
(anti-transglutaminase type 2 IgA) and compatible findings
at duodenal histology, including surface enterocyte damage,
increased intraepithelial lymphocytes (IELs), crypt hyper-
plasia and villous atrophy being considered the principal
hallmark [4].
Although the aforementioned mucosal alterations are
not completely specific to CD, histology is considered the
gold standard for its diagnosis in adults: therefore the
close collaboration between clinicians and pathologists
is required as well as the availability of a standardised
classification in order to obtain correct comparable diag-
noses [5]. In 1990 Marsh [6] proposed a classification
describing four types of lesions named: type 1 or infiltrative
with an increased number of IELs, type 2 or infiltrative-
hyperplastic characterised by an increased number of IELs
plus crypt hyperplasia, type 3 or flat/destructive with the
above lesions plus villous atrophy, and lastly type 4 or atro-
phic/hypoplastic with a normal number of IELs and crypts
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and absence of villi. According to the Marsh criteria
revision proposed by Oberhuber et al. [7] in 1999, the
atrophic type 3 lesion was subdivided in 3a, 3b and 3c
in the presence of mild, marked and total villous atrophy
respectively (Marsh-Oberhuber classification). Another
classification classifies CD damage simply as atrophic
and non-atrophic [8].
A further factor, which strongly facilitates CD diagnosis,
is the response to a gluten-free dietary regimen (GFD)
usually leading to the improvement/disappearance of
symptoms together with the normalisation of antibody
titres and duodenal histology. Therefore, in the major-
ity of cases, a second histology to confirm the diagnosis
is not required when the clinical status is silent and
auto-antibodies negative. A great amount of data has
been published on the histological criteria for CD diag-
nosis: less information is available though about the
histological modifications during GFD and the ways to
compare histological reports before and after GFD.
This is a crucial point for both the correct classification
of CD and related patient management in view of the
recent data showing the persistence of villous atrophy
in spite of the complete adherence to GFD [9, 10].
Therefore, the aim of our study was to highlight the
histology of the treated coeliacs, to show how it would
vary within a biopsy piece and thus to apply a new pro-
portional method to evaluate the duodenal biopsies from
coeliac patients at diagnosis and during follow-up.
Methods
Patients and study design
The retrospective series included CD patients attending
the Centre for the Prevention and Diagnosis of Coeliac
Disease and the Pathology Unit of Fondazione IRCCS
Ca’ Granda-Ospedale Maggiore Policlinico in Milan,
Italy. The “Centre for the Prevention and Diagnosis of
Coeliac Disease” is a tertiary referral centre collecting
cases from the Lombardia region, northern Italy. The
studied cohort was collected from 1st January 2013 to
the 1st June 2013 included patients diagnosed between
2000 and 2012. CD was diagnosed in accordance with the
internationally accepted criteria [5] and all the consecutive
patients with duodenal histology at diagnosis (following a
gluten-containing diet) and after at least one year on GFD
were enrolled. Patients with IgA deficiency were excluded
from the study. The CD onset was classified as: classical
(diarrhoea, weight loss, longitudinal growth retardation),
non-classical (dyspepsia, anemia, hypertransaminasemia,
osteopenia, etc.), associated with the presence of derma-
titis herpetiformis or during a screening programme on
first-degree relatives [11].
The study was carried out in accordance with the na-
tional law on retrospective studies (laws 571/2013 and
572/2013) and approved by the “Fondazione IRCCS Ca’
Granda Ethics Committee”. In accordance with the regu-
latory laws 571/2013 and 572/2013 the need for patients
consent was waived.
Upper gastrointestinal endoscopy and histopathological
evaluation
Upper gastrointestinal endoscopy and biopsies were per-
formed with a flexible endoscope (Olympus, Japan) and
standard bioptic forceps (Boston Scientific, USA). Four
correctly oriented biopsy specimens were taken from the
duodenum for every patient. Briefly, the samples were
oriented on adhesive filter paper, fixed in a 10 % formalin
buffer and paraffin embedded. Sections (3 μm thick) were
cut from each block and hematoxylin/eosin stained. IELs
were counted by means of anti-CD3 immunohistochemical
staining (monoclonal mouse anti-human CD3 clone
F7.2.38, Dako, Italy) [12].
The duodenal histology was independently evaluated
by two expert pathologists (SF and SB), who were unaware
of the patient’s disease history and clinical findings. An
Olympus DMD 108 microscope was used for analysis.
Power fields (PFs) 200X manignification (650x490 μm)
were acquired for examinations Two different methods
were used to define duodenal injury. The first method was
the classical Marsh-Oberhuber scale (MO method) [7].
Briefly, the subsequent criteria were used: i) villous atro-
phy was classified as mild when villi were short or blunted
(3a), marked when only short tent-like villi were seen (3b)
and total when villi were absent (3c); ii) crypt hyperplasia
was considered when dealing with more than two crypts
for each villus; iii) IELs were counted on anti-CD3 stained
sections and the number of 25 lymphocytes/100 entero-
cytes was used as cut-off. When the above mentioned
alterations were absent, the duodenal mucosa was con-
sidered normal (0 type) [8]. In the second method,
named “EF method” and elaborated by two of the authors
(LE and SF), the whole biopsies were observed by each
pathologist. When heterogeneity in morphology and/or
IELs number was observed, ten PFs for each biopsy
piece were considered and analysed according to the
Marsh-Oberhuber scale. The different grades of lesions
were recorded as percentages. For each patient the quantifi-
cation of the different grades observed rather than a single
one (the worst) was then obtained.
In case of discordance between the two pathologists
the mean value was considered. Supplementary sections
were cut to reach the appropriate number of PFs when
needed. The report based on the application of the EF
method, described the different proportions of the area
covered by each Marsh-Oberhuber grade, while the MO
method considered only the worst one.
An example of the EF analytical method is reported in
the Additional files 1, 2 and 3, where two (Additional
files 2 and 3) ten-PF sequences are provided.
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Statistical analysis
All the assumptions were verified by software SPSS ver-
sion 18 (IBM SPSS, Italy), and a p value <0.05 two tails
was considered as statistically significant. Kolmogorov-
Smirnov’s test was used to assess the normal distribution
of the data. Continuous variables were analysed with the
ANOVA one-way variance test. The significance level
was further verified by multiple-comparison analysis with
Tukey’s test. Categorical variables were compared by χ2
(chi square) or Fisher’s exact tests. Correlations were ana-
lysed by Pearson or Spearman’s tests.
In order to evaluate the level of agreement between the
two pathologists, the kappa statistic was used with values
near zero indicating chance agreement only, while values
near the maximum of 1 being consistent with perfect agree-
ment: a good acceptable agreement was considered for
k >0.80 [8]. Data were shown as mean ± standard deviation.
Results
Clinical and histological characteristics of the coeliac
patients examined
The clinical and histological characteristics of 69 con-
secutive CD patients satisfying the entry criteria were
retrospectively analysed and a total 2,760 PFs observed.
The study cohort was composed by 17 (24 %) males and
52 (76 %) females, with a mean age at diagnosis of 39 ±
15 years (range 14–69), following a gluten-free regimen
for a 4 ± 3 years mean period (range 1–13); 12 (17 %) pa-
tients presented an associated autoimmune disease
(Hashimoto’s thyroiditis in 9 cases, alopecia in two and
Sjogren’s disease in one). As to clinical presentation 34
(50 %) patients had a classical onset, 25 (36 %) were
non-classical, 7 (10 %) had been diagnosed during famil-
ial screening and 3 (4 %) presented with dermatitis her-
petiformis. According to the MO method, Table 1 details
the histological grade at diagnosis and during GFD. Of
interest, the worst histological findings were observed in
patients with non-classical clinical onsets including fa-
milial screening and dermatitis herpetiformis. In detail,
3c grades more often occurred in the non-classical group
than in the classical one (96 % vs. 74 %, p <0.05). Gender
and age at diagnosis did not influence the MO score. As
from Table 1, at diagnosis 72 % CD patients were graded
3c; GFD achieved a considerable redistribution of MO
scores towards mild atrophy (3a) or non-atrophic lesions
(0, 1 and 2); 32 CD patients resulted non-atrophic, mild
(3a) and moderate (3b) atrophy increased from 20 to 29
cases and severe atrophy (3c) decreased from 49 to 8.
Similarly, percentage of atrophy decreased after gluten
withdrawal applying the EF method (Fig. 1). Of relevance,
37 (53 %) patients retained an atrophic picture when
analysed according to the MO method (Table 1). As
shown in Fig. 2, IELs significantly decreased during GFD.
No demographic factors among those examined (type of
presentation, gender and age) significantly correlated with
the improvement of the duodenal mucosa; of interest, the
GFD duration failed to influence the histological findings
(see next paragraph).
Analysis of coeliac patients with persistence of duodenal
atrophy
According to the MO method, 37 treated CD patients
(9 males and 28 females, age at diagnosis 39 ± 17 years,
GFD duration 3 ± 3 years) retained duodenal atrophy.
Again, the demographic parameters of this group did
not show any statistical difference compared to the 32
treated CD patients (8 males and 24 females, age at
diagnosis 33 ± 12 years, GFD duration 4 ± 3 years) without
duodenal atrophy. Out of the 37 CD patients with duodenal
atrophy, the sub-grade improved from severe to moderate/
mild atrophy or from moderate to mild in 26 patients,
whereas in the remaining 11 patients (11 females, age at
diagnosis 40 ± 18 years, GFD duration 4 ± 4 years) the level
of atrophy did not change. Again, no demographic or clin-
ical differences were found between these two groups. On
Table 1 Histological findings of 69 coeliac patients at diagnosis
and during their gluten-free diet (GFD), according to the
Marsh-Oberhuber classification
Marsh-Oberhuber grade At Diagnosis During GFD
N (%) n (%)
0 0 (0) 20 (29)
1 0 (0) 11 (17)
2 0 (0) 1 (1)
3a 10 (14) 17 (25)
3b 10 (14) 12 (17)
3c 49 (72) 8 (11)
GFD gluten-free diet
Fig. 1 Distribution of duodenal damage (Marsh-Oberhuber grading)
in untreated (following a gluten containing diet) and treated
(following a gluten free diet) coeliac patients applying the EF
method (see Methods section)
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analysing the 11 unchanged patients according to the EF
method, their histological pattern appeared more complex
than that described by the traditional MO method (the
relevant results are detailed in Table 2 and Fig. 3). As from
Table 2, the second analysis provided different histological
results; in detail, 8 treated CD patients were considered im-
proved, 2 worsened and only one unchanged.
The k test for the inter-observer agreement resulted
0.91 ± 0.25.
Discussion
The present study focused on the evaluation of duodenal
biopsies from CD patients before and after GFD. The
application of a novel approach (EF method) instead of
the classical qualitative one (MO method) led to signifi-
cant changes in the histological reports, enabling the
distinction of patients with different evolution outcomes
of the duodenal damage.
Although different systems have been proposed to
classify the CD duodenal damage (i.e. the Marsh score
[13] and its modification by Oberhuber [7] and the re-
cently introduced Corazza-Villanacci grading [8]), no
approach to follow a CD patient’s evolution has until now
been proposed and the dietary state has been rarely
considered. The introduction of a new method appeared
necessary in case of unchanged responses under the
Marsh-Oberhuber classification (the worldwide referral).
Previous studies analysed the number of IELs and the vil-
lus height/crypt depth ratio [14–16] or the villous area
[17] and their relationship to gluten intake; however, such
parameters appear difficult to apply in a clinical setting,
directly correlated with the Marsh grade, and thus do not
prove useful when this grade is unmodified.
At present, the evaluation of duodenal histology
does not differ whether CD patients are or are not on
a GFD regimen, as the analysis is mainly focused on
spotting the presence of an architectural damage (at-
rophy). These parameters have been summarised in the
Marsh-Oberhuber classification and strongly influence the
specialists in their clinical/therapeutic decisions, especially
when the histological pattern is unmodified [18]. However,
the effects of GFD can be interpreted for further diagnos-
tic clues. Our findings suggest that in adult CD patients,
even those on a strict dietary regimen, the histological re-
sponse can be slow (or absent) and that mucosal atrophy
does not always turn into complete/partial normalisation
[9, 10]. This result has been reported by different studies
[19] and corroborated by data from videocapsule en-
doscopy studies, consistent with the persistence of macro-
scopic signs of intestinal atrophy with a skip fashion [20].
Fig. 2 Number of duodenal intraepithelial lymphocytes (IELs) in
untreated (gluten +) and treated (gluten -) coeliac patients. Means
and standard deviations are reported in the plot
Table 2 Histological analysis results obtained with the EF method (see Methods section) in 11 coeliac patients presenting the same
grade before and after gluten withdrawal when analyzed by the classical Marsh-Oberhuber scoring system
Marsh-Oberhuber grade (%)a
At Diagnosis During GFD
Patient 3a 3b 3c IELs % 0 1 2 3a 3b 3c IELs % Years after diagnosis (n) Outcome
1 0 0 100 31 0 0 0 15 0 85 48 3 I
2 0 0 100 23 0 0 0 50 35 15 45 2 I
3 10 90 0 47 0 0 0 0 95 5 64 13 W
4 0 0 100 49 50 20 0 0 0 30 31 9 I
5 100 0 0 4 20 0 5 75 0 0 12 1 I
6 0 100 0 53 0 0 0 0 100 0 35 7 U
7 0 40 60 27 0 0 0 0 0 100 34 1 W
8 0 0 100 56 0 0 5 0 20 75 61 1 I
9 0 0 100 45 0 0 0 0 40 60 38 6 I
10 0 0 100 55 0 10 0 0 30 60 32 1 I
11 70 30 0 42 0 0 0 20 80 0 46 2 I
a % of area covered, IELs intraepithelial lymphocytes, GFD gluten-free diet, I improved, MO Marsh-Oberhuber, W worsened, U unchanged
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Again, during a gluten-free regimen, serological tests
(i.e. anti tissue transglutaminase IgA) are associated with
clinical responses but do not correlate with the histological
improvement of the duodenal mucosa (mucosal healing)
[21]. The gap between serological and endoscopic/histo-
logical findings represents a potential problem for patient
management in case of persistent mucosal atrophy. In their
study Kaukinen et al. [21] underlined that the occasional
ingestion of gluten is not associated with any increase
in anti-transglutaminase IgA titers. Interestingly, another
series reported only minimal mucosal changes after the
controlled ingestion of gluten [22]. Moreover, there is
evidence that different types of food commonly believed
gluten-free, in fact contain gluten traces [23] and that
an accurate diet analysis often reveals the incomplete
adherence to GFD thus explaining the persistent mucosal
atrophy or removing the suspicion of a refractory sprue
[24, 25]. Autoptic studies [26] showed a progressive de-
crease of mucosal injury from the proximal to the distal
tract of the small intestine; thus, the clinical picture can
reflect the longitudinal involvement of the small bowel ra-
ther than the type of mucosal damage [27]. Additionally,
the histological damage in naïve patients is often patchy
[28, 29]. For this reason, in order to minimise the risk of
under-estimation, the evaluation of at least 4 oriented
duodenal endoscopic biopsies is strongly recommended.
The reason underpinning the persistence of villous at-
rophy in treated CD is not easy to understand, although
a miRNA signature might be involved [20]. In our tertiary
referral Centre, a significant proportion of CD patients were
referred to undergo complete endoscopic investigations,
highlighting how much the need to compare duodenal hist-
ology before and after GFD is particularly felt, in order to
proceed with a watchful follow-up in selected cases. The
above data led to a relevant question, i.e. does the incom-
plete normalisation of the intestinal mucosa represent a risk
factor for CD complications? If yes, the current data and
international guidelines on CD follow-up may suggest the
need for further biopsies after diagnosis, at least until some
mucosal healing is present. Therefore, the opportunity of
quantifying the damage and evaluating its trend would be
important.
Since some symptoms or complications of CD are
correlated with mucosal damage (e.g., osteoporosis) [30],
and other ones are caused by autoantibodies (e.g., infertility)
[31], mucosal biopsy and serological tests should be consid-
ered complementary, and the quantitative evaluation of
mucosal atrophy proves helpful in the evaluation of clinical
findings and patient management.
When applying the EF method to patients with persistent
duodenal atrophy, 91 % of cases changed the histological
assessment, with a regression in 72 % or even a progression
in 18 %.
Whilst the simple detection of atrophy in the duodenal
mucosa of naïve patients is enough to make a correct
diagnosis (as in the Corazza-Villanacci grading), the con-
text dramatically changes when dealing with patients on
GFD, for whom the main question is about the presence
or not of any histological improvement. The answer to this
question requires a more specific scoring system. A pos-
sible problem is represented by the loss of inter-observer
agreement when the number of grades increases. In our
study the k test showed good agreement levels but we
Fig. 3 Duodenal histology from a coeliac patient on a gluten-containing
diet showing a homogenous Marsh-Oberhuber 3c lesion (a). In b, the
duodenal histology from the same patient following a gluten-free
diet is reported showing different grades of damage (3c on the left
side of the panel and 3a on the right side). Using the Marsh-Oberhuber
classification the two biopsies will be classified as 3c although presenting
a different pattern
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suggest that this type of analysis should be used in tertiary
settings by expert pathologists.
Moreover, the possible availability of drug-based ther-
apies for CD in the next future would add to the interest
in systems, such as the EF method, aimed at comparing
duodenal histology before and after GFD, In such a case,
the judgment about the improvement of duodenal atro-
phy will be pivotal in the therapeutic decision-making
process [2].
However, some weak points of the study need to be
discussed. The study has a retrospective design and thus
prospective series are necessary to evaluate the long term
clinical impact and prognosis of patients with an un-
changed MO classification but showing a different finding
with the EF one; in particular, if unchanged or worsened
duodenal histology with the EF method has an increased
risk of complications. Interpretation of duodenal histology
could be challenging due to the patchy nature of CD
damage in some circumstances and the need of a strict
collaboration between clinical gastroenterologist and path-
ologist is essential. Moreover, the EF comparison between
duodenal histology at diagnosis and during follow up
could be performed only in case of correct orientation of
the samples (not always possible). In our study the time
between diagnostic and follow-up biopsy is not uniform
and a dietetic questionnaire was impossible to ascertain
the correctness of the GFD.
Noteworthy, this retrospective study was conducted
in a tertiary referral centre where complicated or challen-
ging cases are managed; thus, a different result could be
present in other scenarios where dedicated and/or expert
personnel are absent. Another point about the EF method
is the cost analysis in the light of a possible clinical benefit;
in fact, the EF method is time consuming and imperfectly
oriented biopsies could introduce the necessity of an in-
creased number of samples per patient.
Conclusions
Overall, the present results indicate that duodenal biopsies
should be analysed with different methods depending on
the clinical setting: is the naive patient affected by CD i.e.
does the patient present any duodenal atrophy? In this
case the pathologist can apply a simple score that indicates
whether the subject presents any atrophy (Marsh 3 grade)
or mild enteropathy (Marsh 1 or 2 grades) or has a normal
duodenum (Marsh 0). When dealing with treated CD
patients the clinical question changes to: has histology
improved or not? In other words, has the duodenal mu-
cosa shown the “tendency” to improve/normalise? In such
a setting, a careful approach comparing the biopsies ac-
quired during gluten ingestion with those taken on GFD,
as with the proposed EF method, would precisely indicate
the patient’s evolution.
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